Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Highlights•First malaria vaccine RTS, S induces anti-sporozoite antibodies to protect
children.•Whole-sporozoite vaccines induce T cells and antibodies and confer field …

There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a
clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II …

The symptoms of malaria occur during the blood stage of infection, when parasites invade
and replicate within human erythrocytes. The PfPCRCR complex, containing PfRH5 (refs.,) …

BACKGROUND The biology of Plasmodium vivax is markedly different from that of P.
falciparum; how this shapes the immune response to infection remains unclear. To address …

Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver
stages and the disease-causing blood stages of the human malaria parasite Plasmodium …

Plasmodium falciparum malaria drives immunoregulatory responses across multiple cell
subsets, which protects from immunopathogenesis, but also hampers the development of …

Understanding mechanisms of antibody synergy is important for vaccine design and
antibody cocktail development. Examples of synergy between antibodies are well …

Abstract Purpose of Review The objective of this review was to provide an update on recent
malaria epidemiology, both globally and in non-endemic areas, to identify the current …

Infections with Plasmodium falciparum and Plasmodium vivax cause over 600,000 deaths
each year, concentrated in Africa and in young children, but much of the world's population …